26U
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more
26U (26U) - Total Assets
Latest total assets as of June 2025: €54.52 Million EUR
Based on the latest financial reports, 26U (26U) holds total assets worth €54.52 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
26U - Total Assets Trend (2021–2024)
This chart illustrates how 26U’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
26U - Asset Composition Analysis
Current Asset Composition (December 2024)
26U's total assets of €54.52 Million consist of 10.6% current assets and 89.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.4% |
| Accounts Receivable | €1.52 Million | 2.7% |
| Inventory | €1.32 Million | 2.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €49.38 Million | 88.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how 26U's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 26U's current assets represent 10.6% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, down from 91.2% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 88.9% of total assets.
26U Competitors by Total Assets
Key competitors of 26U based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
26U - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - 26U generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - 26U is currently not profitable relative to its asset base.
26U - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.50 | 0.92 | 0.92 |
| Quick Ratio | 1.07 | 0.72 | 0.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.65 Million | € -555.00K | € -555.00K |
26U - Advanced Valuation Insights
This section examines the relationship between 26U's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 46180.0% |
| Total Assets | €55.54 Million |
| Market Capitalization | $248.33K USD |
Valuation Analysis
Below Book Valuation: The market values 26U's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: 26U's assets grew by 46180.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for 26U (2021–2024)
The table below shows the annual total assets of 26U from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €55.54 Million | +46180.00% |
| 2023-12-31 | €120.00K | -99.15% |
| 2022-12-31 | €14.05 Million | +10227.94% |
| 2021-12-31 | €136.00K | -- |